AstraZeneca's Dapagliflozin tablets get DCGI nod; will soon be used to treat patients with chronic kidney disease

AstraZeneca Pharma India on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the treatment of patients with chronic kidney disease.

The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.

Dapagliflozin tablet 10 mg is now approved for additional indication, for the treatment of patients with chronic kidney disease(CKD) up to Stage III, it added.

The receipt of this permission paves way for the launch of the product into a new disease area to nephrologists in India, the filing said.

FPJ Shorts

'At The Right Valuation...': Adar Poonawalla's Tweet Goes Viral As Reports Swirl Around Indian Businessman Emerging As Frontrunner To Buy IPL Team RCB

'It's Not Navaratri, It's Nun-Ratri:' Viral Video Shows Woman Dressed As 'The Nun' Playing Garba In Bhopal; Netizens Spark Memefest

Planning Travel From Upcoming Navi Mumbai International Airport? Check Out Premium Hotels Within 40-Minute Drive

'I Am Not Managing This...': Anya Singh Reveals If The Ba***Ds Of Bollywood Season 2 Is Happening | FPJ Exclusive

In July 2020, the company had said that it has received DCGI nod for Dapagliflozin tablets for treatment of patients suffering from heart failure with reduced ejection fraction.

The drug is also sold in the country as a diabetic medicine used for lowering blood sugar in adults with type 2 diabetes.

Read Also

Pfizer withdraws application for emergency use of its COVID-19 vaccine in India